Update: See our article discussing notable points from the Draft Guidelines.
Following its Phase 2 Consultations, on December 19, 2024, the Patented Medicine Prices Review Board (PMPRB) released its new Draft Guidelines and accompanying Overview. The deadline for providing submissions on the Draft Guidelines is March 19, 2025. The PMPRB continues to plan to release its final Guidelines in 2025.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
2023-2024 Pan-Canadian Pharmaceutical Alliance impact report
On November 22, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) released its 2023-2024 impact report.Read More -
2024 highlights in Canadian life sciences IP and regulatory law
In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and regulatory law.Read More -
New PMPRB Draft Guidelines outline administrative process for excessive price hearing recommendations
On December 19, 2024, the Patented Medicine Prices Review Board (PMPRB) released its Draft Guidelines for PMPRB Staff regarding Administrative Process for Excessive Price Hearing Recommendation (Draft...Read More